Pages that link to "Q37378498"
Jump to navigation
Jump to search
The following pages link to Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema (Q37378498):
Displaying 50 items.
- The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies (Q26744317) (← links)
- Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes (Q26785454) (← links)
- Dysglycemia after renal transplantation: Definition, pathogenesis, outcomes and implications for management (Q26795773) (← links)
- Safety of dipeptidyl peptidase 4 inhibitors: a perspective review (Q26863262) (← links)
- Alogliptin benzoate for management of type 2 diabetes (Q28083933) (← links)
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes (Q33562235) (← links)
- Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report (Q33751504) (← links)
- Drug-induced visceral angioedema (Q34288820) (← links)
- Safety of ACE inhibitor therapies in patients with chronic kidney disease (Q34434606) (← links)
- Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome (Q34752755) (← links)
- Brazilian guidelines for the diagnosis and treatment of hereditary angioedema (Q35188409) (← links)
- Clinical applications of drug desensitization in the Asia-Pacific region (Q35502326) (← links)
- Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use (Q35833722) (← links)
- Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells (Q36174657) (← links)
- Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patient (Q36327950) (← links)
- Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model (Q36470223) (← links)
- Role of RACK1 in the differential proliferative effects of neuropeptide Y(1-36) and peptide YY(1-36) in SHR vs. WKY preglomerular vascular smooth muscle cells (Q36699796) (← links)
- Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. (Q36701703) (← links)
- Angioedema Related to Angiotensin-Converting Enzyme Inhibitors: Attack Severity, Treatment, and Hospital Admission in a Prospective Multicenter Study (Q37016647) (← links)
- The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups (Q37502682) (← links)
- Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema (Q37524447) (← links)
- Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions (Q37778379) (← links)
- Vildagliptin: a review of its use in type 2 diabetes mellitus (Q37801906) (← links)
- Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. (Q37888004) (← links)
- Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment (Q37888162) (← links)
- A review of gliptins in 2011. (Q37965612) (← links)
- Achieving glycemic control in patients with type 2 diabetes and renal impairment (Q38065109) (← links)
- Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes (Q38091380) (← links)
- Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs. (Q38107546) (← links)
- Angioedema with normal laboratory values: the next step (Q38131740) (← links)
- Drug-induced angioedema: experience of Italian emergency departments (Q38161456) (← links)
- Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes (Q38189114) (← links)
- The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. (Q38205588) (← links)
- Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox (Q38219490) (← links)
- Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions (Q38253580) (← links)
- DPP-4 inhibitors: a patent review (2012 - 2014). (Q38284522) (← links)
- DPP-4 inhibitors: focus on safety (Q38285608) (← links)
- Management of angioedema without urticaria in the emergency department (Q38314955) (← links)
- Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes (Q38335751) (← links)
- Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. (Q38401198) (← links)
- Angioedema induced by cardiovascular drugs: new players join old friends (Q38539515) (← links)
- Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation (Q38647717) (← links)
- The Story of Angioedema: from Quincke to Bradykinin (Q38855032) (← links)
- Diabetes mellitus and the skin. (Q38901757) (← links)
- Uncertainties around incretin-based therapies: A literature review (Q39145953) (← links)
- Treatment of ACEI-related angioedema with icatibant: a case series. (Q39194480) (← links)
- Angioedema Triggered by Medication Blocking the Renin/Angiotensin System: Retrospective Study Using the French National Pharmacovigilance Database (Q41018758) (← links)
- Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. (Q41422603) (← links)
- Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature (Q41989294) (← links)
- Pathogenesis of Drug Induced Non-Allergic Angioedema: A Review of Unusual Etiologies (Q42649822) (← links)